TSH Norms in Pregnancy: Trimester Targets and Clinical Tactics

Introduction

Pregnancy is a physiological state in which thyroid function reference intervals shift downward. Managing the thyroid by standard non-pregnant lab ranges is a common clinical error: what looks "normal" in a non-pregnant woman can be occult hypothyroidism with direct consequences for fetal CNS development.

This article is a practical guide to trimester-specific TSH targets, tactics for anti-TPO positive patients, levothyroxine dosing, and iodine prophylaxis — based on the 2017 American Thyroid Association Guideline (PMID 28056690) and 25 years of evidence.

Why norms are different: thyroid physiology in pregnancy

Pregnancy reshapes thyroid physiology at several levels:

▸ hCG mimics TSH — in the first trimester, human chorionic gonadotropin has structural homology with thyrotropin and directly stimulates the thyroid via the TSH receptor. Physiologically this causes TSH to fall at the hCG peak (weeks 8–14) — the classical observation by Glinoer (PMID 9183570).
▸ Estrogens raise TBG — thyroxine-binding globulin increases 1.5–2-fold. Total T4 rises while free fT4 remains relatively stable.
▸ Iodine requirement increases by 50% — driven by renal clearance and fetal need.
▸ The fetus depends on maternal hormone until weeks 18–20 — the fetal thyroid does not begin meaningful function until the second half of pregnancy.

The clinical principle that follows: the upper TSH bound in pregnancy is lower than in non-pregnant women — regardless of the generic lab reference range printed on the result.

Trimester-specific TSH targets

Per the 2017 ATA Guideline (Alexander et al., PMID 28056690), the normal range and the treatment target are not the same thing:

▸ Normal range in pregnancy — the pregnancy-specific intervals provided by your laboratory (or by a lab with a similar population and the same assay)
▸ If no such range exists — an upper limit of about 4.0 mIU/L; for most assays this is roughly 0.5 mIU/L below the non-pregnant upper limit
▸ Planning pregnancy on levothyroxine — TSH between the lower reference limit and 2.5 mIU/L
▸ Pregnant on levothyroxine — lower half of the pregnancy-specific range; if unavailable, < 2.5 mIU/L

With positive anti-TPO, the threshold for a treatment decision is lower: at TSH above 2.5 mIU/L levothyroxine may be considered, and above the pregnancy-specific range it is recommended (ATA 2017, Recommendation 29). Anti-TPO positive patients have reduced thyroid functional reserve and respond worse to the rising demands of pregnancy at any given TSH.

If your laboratory has no pregnancy-specific range, the ATA reference point is about 4.0 mIU/L. Taking the non-pregnant range from the generic lab report as the pregnancy norm is an error. The opposite error is calling TSH 2.5–4.0 hypothyroidism in every pregnant woman: 2.5 is a treatment target, not the edge of normal.

When to start levothyroxine

Initiation tactics during pregnancy (ATA 2017, Recommendations 27–29; at TSH > 2.5 mIU/L, anti-TPO is checked first):

▸ Overt hypothyroidism (TSH above the pregnancy range + low fT4) — treatment is mandatory. Start without delay; the dose is set by the physician.
▸ TSH > 10 mIU/L — levothyroxine is recommended even with normal fT4 and negative anti-TPO.
▸ TSH above the pregnancy range + anti-TPO positive — levothyroxine is recommended.
▸ TSH above the pregnancy range but < 10 + anti-TPO negative — levothyroxine may be considered (weak recommendation).
▸ TSH from 2.5 to the upper limit of the pregnancy range + anti-TPO positive — levothyroxine may be considered (weak recommendation); the decision is individual and takes obstetric history into account.

When treatment is indicated, start it right away. "Wait and see" is not a tactic in pregnancy thyroid management.

Maternal and fetal risks of untreated hypothyroidism

Uncompensated hypothyroidism during pregnancy is associated with increased rates of:

▸ Spontaneous miscarriage — increased risk
▸ Gestational diabetes
▸ Hypertension and preeclampsia
▸ Preterm birth
▸ Placental abruption
▸ Postpartum hemorrhage
▸ Reduced child cognitive development — children of women with severe untreated hypothyroidism in the 2nd trimester scored 7 points lower on IQ testing (Haddow et al., PMID 10451459)

This evidence base is why ATA 2017 recommends detecting and treating hypothyroidism in pregnancy. The cost of missing the diagnosis is not "minor deviation" — it is irreversible neurodevelopmental impact.

Anti-TPO and fertility: a standalone risk even at normal TSH

Positive anti-TPO with normal TSH is an independent risk factor for:

▸ IVF failure — reduced implantation and live birth rates
▸ Postpartum thyroiditis — develops in 33–50% of women with antibodies in the 1st trimester (ATA 2017)

ATA 2017 allows 25–50 µg levothyroxine with positive anti-TPO and normal TSH in only two situations, and only as a weak recommendation ("may be considered"): prior pregnancy loss (Recommendation 14; Negro et al., PMID 16621910) and assisted reproduction/IVF (Recommendation 21). For non-pregnant women attempting natural conception the evidence is insufficient, and no recommendation is made (Recommendation 19). To prevent postpartum thyroiditis, levothyroxine is ineffective and not recommended (Recommendation 92). The logic of treatment in these situations: compensate the reduced thyroid functional reserve before pregnancy demands exceed it.

More on the role of anti-TPO, selenium, and vitamin D in reducing antibody titers — in Iodine and thyroid: 5-step protocol.

Iodine in pregnancy: dose, form, limitations

A pregnant woman needs about 250 µg of iodine per day (ATA 2017, Recommendation 5; WHO) — this is total intake from food and supplements combined, not the dose of a tablet.

Practical rules:

▸ A 150 µg daily iodine supplement as potassium iodide — in most regions ATA recommends it for every woman planning pregnancy or pregnant (Recommendation 6). Ideally start 3 months before planned conception.
▸ Women already on levothyroxine or treated for hyperthyroidism do not need to start an iodine supplement (Recommendation 8).
▸ NOT kelp, NOT Lugol's solution — herbal and alcohol-based preparations give uncontrolled doses (from 150 µg to 6 mg per drop) and risk iodine-induced thyroiditis. Sustained intake above 500 µg/day should be avoided in pregnancy (Recommendation 10).
▸ In autoimmune thyroiditis (anti-TPO positive) — the ATA recommendation is the same: a 150 µg daily supplement; antibody positivity is not named as an exception. ATA 2017 does not recommend selenium supplements for anti-TPO positive pregnant women (Recommendation 12): trial results are inconsistent.

The full panel: what to check and when

Minimum lab workup for a pregnant woman with hypothyroidism or AIT:

▸ At diagnosis: TSH, fT4, anti-TPO, anti-Tg
▸ At preconception: + fT3, ferritin, vitamin D, selenium (if available), urinary iodine (when indicated)
▸ On levothyroxine therapy and with positive anti-TPO: TSH + fT4 about every 4 weeks until mid-pregnancy and at least once near week 30 (ATA 2017, Recommendation 33)

Levothyroxine dose during pregnancy typically increases by 25–30% from baseline due to increased demand (Abalovich et al., PMID 17948378). If a woman conceives on an already titrated dose, the increase is often needed by weeks 5–6.

Levothyroxine administration rules:

▸ Strictly fasting 30–60 minutes before breakfast
▸ Do not combine with iron, calcium, or multivitamins with iron or calcium — they reduce absorption; keep them no closer than 4 hours to the tablet
▸ Water only — not coffee, not milk

More on the deiodinase system and T4→T3 conversion that determines replacement efficacy — in T4→T3 conversion and functional hypothyroidism.

Monitoring during and after pregnancy

Surveillance schedule:

▸ Until mid-pregnancy (~week 20) — TSH + fT4 about every 4 weeks. Peak sensitivity period for undercompensation.
▸ Around week 30 — at least one more TSH check (Recommendation 33).
▸ After delivery — levothyroxine returns to the pre-pregnancy dose, with TSH about 6 weeks postpartum (Recommendation 37).
▸ Postpartum surveillance — TSH at 3 and 6 months postpartum, particularly in anti-TPO positive women.

Postpartum thyroiditis develops in about 5% of women (1–17% across studies) within the first year after delivery. The classical triphasic course (transient thyrotoxicosis → hypothyroidism → recovery) occurs in about a quarter, another quarter have only the thyrotoxic phase, and half have only hypothyroidism (ATA 2017; Stagnaro-Green, PMID 22312089). With positive anti-TPO in the 1st trimester, postpartum thyroiditis develops in 33–50% of women, and a fraction of these episodes progress to permanent hypothyroidism.

Caution: what not to do

Frequent tactical errors:

▸ Taking the non-pregnant TSH range from the generic lab report as the pregnancy norm — the upper limit in pregnancy is lower; without a pregnancy-specific range, the reference point is about 4.0 mIU/L. The opposite error is calling any TSH above 2.5 hypothyroidism.
▸ Starting an iodine supplement in a woman already on levothyroxine — not needed (ATA 2017, Recommendation 8).
▸ Stopping levothyroxine "because she is pregnant" — the opposite: the dose typically increases by 25–30% during pregnancy.
▸ Checking TSH "once per trimester" — insufficient. Until mid-pregnancy, checks about every 4 weeks are needed.
▸ Using alcoholic Lugol or kelp for iodine prophylaxis — uncontrolled doses, overdose risk.
▸ Ignoring anti-TPO positivity at TSH above 2.5 — here ATA allows levothyroxine (an individual decision), and above the pregnancy-specific range treatment is recommended.

Bottom line

Pregnancy and thyroid disease are not "one TSH check per pregnancy" — they are trimester-by-trimester tactics with trimester-specific targets. The standard that reduces risk for both mother and fetus is three rules:

1. Preconception preparation — assess TSH, anti-TPO, ferritin, vitamin D before conception; on levothyroxine, target TSH between the lower reference limit and 2.5 mIU/L.
2. Checks about every 4 weeks until mid-pregnancy — the most fetus-sensitive period and the period of maximum dose adjustment; once more near week 30.
3. Iodine supplement 150 µg/day from the preconception phase (total intake about 250 µg/day), as potassium iodide (not Lugol, not kelp); not needed for women on levothyroxine.

This is the ATA 2017 baseline (PMID 28056690). Everything else is individualized tactics layered on top.

About the author

I am Dr. Vladimir Pereligyn, endocrinologist and researcher. I specialize in endocrine, metabolic, and autoimmune protocols with a holistic approach and individualized lab diagnostics. Book a consultation — universum.earth/consultation. Daily clinical breakdowns — @md_pereligyn_thyroid.

Sources

• Alexander EK et al. 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. Thyroid 2017. PMID 28056690
• Glinoer D. The regulation of thyroid function in pregnancy: pathways of endocrine adaptation. Endocr Rev 1997. PMID 9183570
• Haddow JE et al. Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child. N Engl J Med 1999. PMID 10451459
• Abalovich M et al. Management of subclinical hypothyroidism during pregnancy. J Clin Endocrinol Metab 2007. PMID 17948378
• Stagnaro-Green A. Approach to the patient with postpartum thyroiditis. J Clin Endocrinol Metab 2012. PMID 22312089
• Negro R et al. Levothyroxine treatment in euthyroid pregnant women with autoimmune thyroid disease. J Clin Endocrinol Metab 2006. PMID 16621910

This article is for informational purposes only and does not replace a medical consultation. Before starting any supplements, changing medication, or undergoing diagnostic procedures, discuss the plan with your physician.

Gestational hyperthyroidism: differentiating hCG-driven thyrotoxicosis from Graves' disease

A suppressed TSH in the first trimester is not automatically pathological. Two clinically distinct entities present with the same lab pattern — TSH < 0.1 mIU/L plus elevated or upper-normal fT4 — and require opposite management.

Gestational transient thyrotoxicosis (GTT) is hCG-mediated. It peaks between weeks 8 and 14 — the same window as physiological hCG elevation — and resolves spontaneously by weeks 14–18 as hCG declines. Prevalence is 1–3% of pregnancies. Severity correlates with hCG level: it is more common in hyperemesis gravidarum, multiple pregnancy, and gestational trophoblastic disease. The patient typically has no prior thyroid history, no goiter, no orbitopathy, and TSH receptor antibodies (TRAb) are negative. Antithyroid drugs are not indicated; management is supportive (hydration, antiemetics, beta-blockers if symptomatic).

Graves' disease in pregnancy affects 0.1–1% of pregnancies. Diagnostic criteria differ from GTT in three ways: (1) TRAb positive — the single most decisive test, (2) symptoms predate pregnancy or persist beyond week 18, (3) thyroid enlargement, ophthalmopathy, or pretibial myxedema may be present. Untreated maternal Graves' has fetal consequences: TRAb crosses the placenta and can cause fetal or neonatal thyrotoxicosis even in mothers euthyroid on antithyroid drugs.

Practical workup of suppressed TSH in pregnancy: order TRAb, fT4, fT3, and clarify symptom timeline. A urine hCG quantitative level helps when GTT is suspected with hyperemesis. Thyroid scintigraphy is contraindicated in pregnancy regardless of differential.

Subclinical hyperthyroidism (TSH suppressed, fT4 normal) without symptoms and without TRAb is not associated with adverse pregnancy outcomes in major cohorts and does not require treatment. Overtreating physiologically low TSH in early pregnancy is a common error and may induce iatrogenic hypothyroidism — which, as covered above, is the more dangerous direction for the fetus.

This differential matters because misclassifying GTT as Graves' leads to unnecessary antithyroid drug exposure in the first trimester — exactly the window of maximum teratogenicity for methimazole.

Antithyroid drug tactics by trimester: PTU, methimazole, and the switch protocol

When pregnancy-associated hyperthyroidism does require pharmacological treatment — confirmed Graves' or severe symptomatic thyrotoxicosis — drug choice is trimester-specific. The choice up to week 16 is clear; what to do after week 16 is not.

First trimester — propylthiouracil (PTU). Methimazole and carbimazole are associated with a characteristic embryopathy (aplasia cutis, choanal atresia, esophageal atresia, abdominal wall defects) when exposure occurs during organogenesis (weeks 6–10). Absolute risk is small (2–4% above background) but the pattern is consistent across cohorts. PTU is recommended through week 16 (ATA 2017, Recommendation 47a). Typical starting dose: 50–150 mg every 8 hours, titrated to the lowest dose maintaining fT4 in the upper third of the non-pregnant reference range — not the middle. Aggressive normalization risks fetal hypothyroidism, because antithyroid drugs cross the placenta freely.

After week 16 — PTU or methimazole. PTU carries a small but real risk of fulminant hepatic failure (~1:10,000 exposures), and the embryopathy concern of methimazole no longer applies after organogenesis. Still, ATA 2017 makes no recommendation on switching (Recommendation 47d): both drugs carry risks, and a switch may bring a period of less-tight control, so the decision is individual. ATA uses a dose ratio of about methimazole 1 : PTU 20 (methimazole 5 mg/day ≈ PTU 100 mg twice daily).

Monitoring on antithyroid therapy: fT4 every 2–4 weeks. TSH lags by weeks and is unreliable as a titration target during active treatment. Maternal TSH below the suppressed pregnancy range while on PTU/methimazole indicates over-treatment and risk of fetal goiter.

TRAb testing follows ATA 2017 (Recommendation 52): measure in early pregnancy in women with prior radioactive iodine or surgery for Graves' (surgical/RAI history does not eliminate the antibody risk) and in women taking antithyroid drugs when pregnancy is confirmed; repeat at weeks 18–22 if TRAb are elevated or antithyroid drugs are still needed at mid-pregnancy. Women in remission after a course of antithyroid drugs do not need TRAb testing in pregnancy. TRAb > 3× upper limit warrants fetal monitoring for goiter and tachycardia via obstetric ultrasound.

Breastfeeding: both PTU (≤ 300 mg/day) and methimazole (≤ 20 mg/day) are compatible. Take immediately after a feed to minimize peak drug transfer.

The ATA 2017 guideline (PMID 28056690) is explicit that pregnancy is not the time to attempt definitive therapy. Radioactive iodine is absolutely contraindicated. Thyroidectomy is reserved for refractory disease and is preferred in the second trimester if surgery is unavoidable.

Levothyroxine dose increase once pregnancy is confirmed: "two extra doses per week"

The article notes that levothyroxine requirements rise 25–30% in pregnancy (Abalovich et al., PMID 17948378). The clinical question that follows: how is this increase implemented in the 4–6 weeks before a confirmatory TSH returns?

ATA 2017 (Recommendation 36; Alexander et al., PMID 28056690) recommends that a woman already on levothyroxine increase the dose by about 20–30% as soon as pregnancy is suspected or confirmed — one practical way is two extra daily doses per week, the scheme tested in the THERAPY trial (Yassa et al., PMID 20463094). For example, a patient taking 100 µg daily (7 tablets per week = 700 µg) moves to 9 tablets per week (≈ 130% of baseline), distributed by taking the usual dose on 5 days and a double dose on 2 days. TSH is then checked about every 4 weeks until mid-pregnancy and at least once near week 30 (ATA 2017, Recommendation 33), and the dose is fine-tuned from there.

The biological rationale: hCG-driven TSH suppression in early pregnancy masks early hypothyroxinemia. Waiting for TSH to rise above target before adjusting the dose leaves the fetus underexposed during the window of CNS development that depends entirely on maternal hormone (weeks 0–18).

Target and individual adjustment:

• Target TSH during pregnancy — the lower half of the trimester-specific range; if no such range is available, < 2.5 mIU/L (ATA 2017, Recommendation 35).
  - The size of the increase depends on the cause of hypothyroidism (e.g., after thyroidectomy or radioiodine more is usually needed) and on preconception TSH; the guideline sets no fixed TSH cut-offs for a smaller or larger step — this is the clinician's judgement.
  - TSH above target at conception means the dose was insufficient: the dose is increased and TSH rechecked sooner, at an interval chosen by the clinician.

Postpartum reversal: drop back to pre-pregnancy dose within 1–2 weeks of delivery, with TSH check at 6 weeks postpartum. Failing to reduce the dose causes iatrogenic thyrotoxicosis, which is a frequent finding at the 3-month postpartum visit when the dose was left unchanged.

Caveat on lab assay: free T4 immunoassays drift downward in the 2nd and 3rd trimesters due to TBG elevation interfering with the assay. A "low" fT4 in late pregnancy with normal TSH is more often an assay artifact than true hypothyroxinemia. When isolated low fT4 is the only finding, repeat with a trimester-specific reference interval, or order total T4 (target = non-pregnant range × 1.5) before adjusting therapy. Equilibrium dialysis fT4 is the gold standard but rarely available in routine practice.